Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

Exit

Acquired byChiesi Pharmaceuticals
Date8/2013

General Information

Offices

Hillerød, DNK
Roskildevej 12 C
Hillerød, 3400, DNK

People

President
Chairman

Tags

Zymenex

Zymenex is a Scandinavian biopharmaceutical company focused on the development and commercialization of novel enzyme replacement therapies for the treatment of life-threatening, rare genetic diseases.

Zymenex is developing several human recombinant enzymes that can be used for therapy within specific disease areas. The products are expected to be able to help patients, who today have serious handicaps, reduced quality of life and a markedly reduced life expectancy. Enzyme replacement therapy is a well-known treatment method and there are a number of products on the market today that validates the company concept.

The company’s Research and Development focuses on Lysosomal Storage Diseases, which is a common name for human diseases, where the ability of the human body to break down specific molecules in the lysosomes in the cells is reduced or impaired. The diseases most often affect children, they are lethal and there is no therapy available today.

Recent Milestones

Videos

Screenshots

Zymenex screenshot
Above: Zymenex Screenshot -- #1
Uploaded: 8/27/13

Sources

  1. Chiesi Farmaceutici Acquires Zymenex (finsmes.com) [edit]
Edit This Page
Last Edited 9/5/13

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize »

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy